Request Demo

Last update 08 May 2025

Ferrous Gluconate

Last update 08 May 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

D-gluconic acid, iron(2+) salt (2:1), Ferric Gluconate, Ferrous Cluconate Syru

+ [9]

Target-

Action

modulators

Mechanism

Fe modulators

Therapeutic Areas

Endocrinology and Metabolic DiseaseHemic and Lymphatic Diseases

Active Indication

Anemia, Iron-Deficiency

Inactive Indication-

Originator Organization-

Active Organization-

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC12H24FeO15

InChIKeyBJBSKTPEFSQVHL-UHFFFAOYSA-L

CAS Registry6047-12-7

View All Structures (2)

Clinical Trials associated with Ferrous Gluconate

NCT06252103

/ CompletedPhase 4IIT

Lactoferrin With Ferrous Gluconate Versus Ferrous Gluconate in Treatment of Iron Deficiency Anemia During Pregnancy

Study Procedures:
All patients will undergo the following:
Informed consent will be obtained from all the participants in this study before enrolling in this study and all participants will be subjected to a detailed clinical assessment including: a detailed history, general, abdominal examinations, Investigations.
History taking:
Personal history: name, age, occupation and address.
Menstrual and obstetric history: Date of LMP, expected date of delivery which will be calculated according to Naegle's rule and gestational age. In addition to history of presence of any menstrual irregularities, duration.
Past History: of Anemia in previous pregnancy, other diseases like Thalassemia, sickle cell anemia, liver or renal diseases or any other condition that may affect hemoglobin.
Medical examination:
General: Assessment of complexion and vital data (blood pressure, pulse, capillary refill)
Abdominal examination to assess fundal height.
Investigations to perform will include:
Laboratory: Complete blood count (microcytic hypochromic anemia) Imaging: Ultrasound to assess biometry to exclude fetal growth restriction. Women will be divided in two groups with 20 in each group, the first group will receive one tab of ferrous gluconate 300mg administered orally twice per day for 4 weeks and the second group will receive lactoferrin sachets 100mg with ferrous gluconate 300mg twice per day for 4 weeks Patients were assigned to take the medication orally; once daily before breakfast, and Pravotin (100 sachets were be dissolved each in ¼ glass of water and taken before breakfast). Patients were advised to avoid the intake of tea, coffee, milk, milk products, antacids and calcium preparation within 2 hours before or after iron capsules.
Women will be told to record side effects as nausea, vomiting, abdominal discomfort and constipation.
Women will have a blood sample (CBC) withdrawn after 2 to 4 weeks to assess rise in pregnant anemia.

Start Date30 May 2023

Sponsor / Collaborator

Ain Shams University

NCT06049693

/ CompletedPhase 4IIT

Iron Prehabilitation and Perioperative Infectious Diseases of Endometrial Cancer Patients

Endometrial cancer patients often have iron deficiency anemia before surgery, which can be effectively treated with oral iron supplementation. Anemia and blood transfusions have been previously associated with perioperative infectious diseases. In the present study the investigators will evaluate the impact of perioperative iron supplementation on the incidence of perioperative infections.

Start Date01 Jan 2023

Sponsor / Collaborator

National & Kapodistrian University of Athens

NCT02271997

/ CompletedPhase 4

Optimizing Iron Suppletion After Roux-en-Y Gastric Bypass (Ironsuppletion)

Multicentre randomized controlled trial to evaluate the optimal treatment for patients who developed an iron deficiency after Roux-en-Y Gastric bypass.

Start Date04 Dec 2014

Sponsor / Collaborator

Rijnstate

100 Clinical Results associated with Ferrous Gluconate

100 Translational Medicine associated with Ferrous Gluconate

100 Patents (Medical) associated with Ferrous Gluconate

668

Literatures (Medical) associated with Ferrous Gluconate

31 Dec 2025·Hematology

Platelet levels before and after iron replacement therapy in patients with iron deficiency anemia

Article

Author: Khan, Muneer ; Meseeha, Marcelle G. ; Tayyab, Hamnah ; Oyeleye, Oluwagbemiga ; Bhatta, Ghanshyam ; Paudel, Asmita ; Talamo, Giampaolo

BACKGROUNDIron deficiency anemia (IDA) is the most common cause of anemia worldwide. Patients with IDA often present thrombocytosis, but little is known about its degree and prevalence, and its response to iron replacement.METHODSWe conducted a retrospective review of 76 consecutive patients with anemia secondary only to iron deficiency. Laboratory data were collected both at baseline and at 3 months after either oral or intravenous iron replacement therapy. We defined thrombocytosis as a platelet count >400 × 10⁹/L.RESULTSThe median age of the patients was 54 years (range, 22-90 years), and 59 of 76 (78%) patients were females. The replacement therapy consisted of oral iron (n = 13), intravenous iron (n = 33), or both (n = 30). The median Hb and ferritin levels at baseline and at 3 months after the iron replacement were 9.9 g/dL and 18 mg/dL, and 12.4 g/dL (p < 0.0001) and 113 mg/dL (p < 0.0001), respectively. Thrombocytosis before and after the iron administration was present in 17 (22%) and 4 (5%) patients, respectively. Regardless of thrombocytosis, the platelet count decreased in 55 (72%) patients. The median platelet level at baseline and at 3 months after the iron replacement was 299 (95% CI, 276-330) and 265 (95% CI, 245-295) × 10⁹/L (p < 0.0001), respectively.CONCLUSIONThrombocytosis is found in about one fifth of patients with IDA at baseline, and it is expected to resolve within 3 months of iron replacement therapy in most of them. Iron administration is associated with a decrease of the platelet counts, even in the absence of preexisting thrombocytosis.

01 Mar 2025·Animal Feed Science and Technology

Essential oil of Curcuma aromatica as a dietary supplement: Evaluation of its effect on growth, haematology, immune response and histopathology in Channa punctata challenged with two pathogenic aeromonads

Author: Sarma, Dandadhar ; Thaosen, Naisringdi ; Das, Rajdeep ; Sarma, Kangkan

A seven-week feeding trial was conducted to examine the effect of dietary inclusion of Curcuma aromatica essential oil (CAEO) as supplementary feed additive on growth performance, haematol. parameters, immunol. responses and histol. changes in Channa punctata.A total of 675 fish (initial body weight of 4.44 ± 0.23 g) were randomly distributed in 27 tanks with 25 fish per tank (3 treatments with 3 replications) and fed with diets containing essential oil extracted from rhizome of Curcuma aromatica (CAEO) at concentrations 0.00, 0.25 and 2.00 mL per kg feed.Each of the exptl. feeding groups was further divided into 3 sub-groups C: not challenged with bacteria, RD-01: challenged with Aeromonas veronii, RD-05: challenged with Aeromonas hydrophila.The first exptl. phase consisted of feeding fish for the first four weeks, and in the second phase, the fish were challenged with LD₅₀ of A. veronii (2.6 x 10⁴ CFU/fish) and A. hydrophila (1.6 x 10⁴ CFU/fish) with continued feeding for remaining three weeks.The final weight gain and specific growth rate were found to be significantly increased (P < 0.05) in the group fed with supplemented diet containing 2.00 mL/kg concentrationCumulative mortality was recorded for 3 wk post-challenge which showed higher percentage of survival rate (>95 %) in groups fed with 2.00 mL CAEO/kg diet, where RD-01 and RD-05 sub-groups had a survival rate of 98 % and 96 %, resp.The haematol. values were significantly higher in both challenged and unchallenged groups fed with 2.00 mL CAEO/kg diet.The total protein content, total Ig concentration and lysozyme activity significantly increased in groups fed with 2.00 mL CAEO/kg diet, in which RD-05 showed the highest values.Comparable histol. differences were prominent in liver and kidney tissues of fish fed with 0.00 and 2.00 mL/kg diets.The study illustrated that the dietary supplementation with 2.00 mL CAEO/kg feed is highly effective to enhance growth and health in Channa punctata and increase bacterial resistance to Aeromonas species.

12 Feb 2025·Journal of Agricultural and Food Chemistry

Is Ferric the Same as Ferrous? Effect of Nutritionally Relevant Iron Species in C. elegans: Bioavailability, Iron Homeostasis, Oxidative Stress, and Cell Death

Article

Author: Michalke, Bernhard ; Bornhorst, Julia ; Hayen, Heiko ; Thiel, Alicia ; Gerisch, Emely ; Gremme, Anna ; Scholz, Johannes ; McColl, Gawain ; Safa Flaih, Zainab Al-Timimi

Iron (Fe) is present in foods and food supplements in a wide variety of Fe species. Caution needs to be paid in the case of overdosing on this essential trace element as adverse effects like neurodegenerative diseases are associated with increased iron levels in the brain. However, knowledge regarding the species-specific effects of nutritionally relevant Fe species is limited. Therefore, we treated the nematode Caenorhabditis elegans (C. elegans) with an overdose of the Fe species iron(III) ammonium citrate (FAC), iron(II) gluconate (FeGlu), and iron(II) chloride (FeCl₂) for 5 and 24 h. While the bioavailability of Fe was highest with FeCl₂ and lowest with FAC, the effects on tested endpoints, such as superoxide dismutase activity, translocation of the transcription factor daf-16 (human FOXO3), mitochondrial reactive oxygen and nitrogen species, and apoptotic cells were similar. This study provides further insights into Fe-species-specific effects on genes related to Fe homeostasis of C. elegans by studying gene expression and investigating C. elegans mutants lacking smf-3, ftn-1, ftn-2, dcytb (f55h2.5), and cp (f21d5.3). Thus, these findings underline the significance of the oxidation state and ligand of Fe species with respect to bioavailability while also identifying the key genes involved in Fe homeostasis in C. elegans.

100 Deals associated with Ferrous Gluconate

External Link

KEGG	Wiki	ATC	Drug Bank
D02394	Ferrous Gluconate	B03AA03	DB14488

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anemia, Iron-Deficiency	-	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASN2010	Not Applicable	Anemia	-	Ferumoxytol	sevdycitat(iasapcfebt) = bfvyubhosg qxcyrqzhqi (anuxogjfef )	Positive	16 Nov 2010
				Ferric gluconate	sevdycitat(iasapcfebt) = ahoetmxfvj qxcyrqzhqi (anuxogjfef )
ASN2010	Not Applicable	Maintenance	155	Ferric Gluconate	svemidpoyn(oindzuslvf) = eouqdplhzn shfkwsvodk (bzfiputkqg ) View more	Positive	16 Nov 2010
				Ferumoxytol	svemidpoyn(oindzuslvf) = mbakqgghqx shfkwsvodk (bzfiputkqg ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis